EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Drug efflux pump deficiency and drug target resistance masking in growing bacteria



Drug efflux pump deficiency and drug target resistance masking in growing bacteria



Proceedings of the National Academy of Sciences of the United States of America 106(20): 8215-8220



Recent experiments have shown that drug efflux pump deficiency not only increases the susceptibility of pathogens to antibiotics, but also seems to "mask" the effects of mutations, that decrease the affinities of drugs to their intracellular targets, on the growth rates of drug-exposed bacteria. That is, in the presence of drugs, the growth rates of drug-exposed WT and target mutated strains are the same in a drug efflux pump deficient background, but the mutants grow faster than WT in a drug efflux pump proficient background. Here, we explain the mechanism of target resistance masking and show that it occurs in response to drug efflux pump inhibition among pathogens with high-affinity drug binding targets, low cell-membrane drug-permeability and insignificant intracellular drug degradation. We demonstrate that target resistance masking is fundamentally linked to growth-bistability, i.e., the existence of 2 different steady state growth rates for one and the same drug concentration in the growth medium. We speculate that target resistance masking provides a hitherto unknown mechanism for slowing down the evolution of target resistance among pathogens.

(PDF emailed within 0-6 h: $19.90)

Accession: 052719930

Download citation: RISBibTeXText

PMID: 19416855

DOI: 10.1073/pnas.0811514106



Related references

Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria. Current Drug Targets 17(6): 702-719, 2015

The effects of gene mutation related to drug resistance and drug efflux pump in extensively drug-resistant tuberculosis clinical isolates. Zhonghua Jie He He Hu Xi Za Zhi 33(7): 505-509, 2011

Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus. Antibiotics 2(1): 28-45, 2013

MexT, an activator protein for the MexEF-OprN multi-drug efflux pump, eliminates induction of the MexAB-OprM multi-drug efflux pump in the presence of N- -L-homoserine lactone. Abstracts of the General Meeting of the American Society for Microbiology 103: K-080, 2003

Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochimica et Biophysica Acta 1794(5): 826-833, 2009

P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochemical Pharmacology 41(3): 349-359, 1991

Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. International Journal of Pharmaceutics 336(1): 12-21, 2006

A model of a transmembrane drug-efflux pump from Gram-negative bacteria. Febs Letters 578(1-2): 5-9, 2004

The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. Respiratory Research 14: 63-63, 2015

Efflux pump-mediated drug resistance in Burkholderia. Frontiers in Microbiology 6: 305-305, 2015

Combating drug resistance in fungi with efflux pump inhibitors. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 451, 2002

Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrobial Agents and ChemoTherapy 57(2): 751-757, 2013

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrobial Agents and ChemoTherapy 56(9): 4806-4815, 2013

Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrobial Agents and ChemoTherapy 48(7): 2415-2423, 2004